• 1. A dual removable activating group enabled the Povarov reaction of N-arylalanine esters: synthesis of quinoline-4-carboxylate esters
  Xiaodong Jia,Shiwei Lü,Yu Yuan,Xuewen Zhang,Liang Zhang,Liangliang Luo Org. Biomol. Chem. 2017 15 2931
• 2. Organic chemistry
  J. Chem. Soc. Abstr. 1921 120 i533
• 3. Determination of electrophilic aromatic reactivities via pyrolysis of 1-arylethyl acetates. Part VII. The total reactivity of quinoline
  R. Taylor J. Chem. Soc. B 1971 2382
• 4. Index of subjects
  J. Chem. Soc. Abstr. 1921 120 ii841
• 5. Organic chemistry
  J. Chem. Soc. Abstr. 1921 120 i297

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Quinolines and derivatives
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives

Research Brief on Ethyl Quinoline-4-carboxylate (CAS: 10447-29-7) in Chemical Biology and Pharmaceutical Applications

Ethyl quinoline-4-carboxylate (CAS: 10447-29-7) has recently gained significant attention in chemical biology and pharmaceutical research due to its versatile scaffold and potential therapeutic applications. This heterocyclic compound serves as a key intermediate in the synthesis of various bioactive molecules, particularly in antimicrobial and anticancer drug development. Recent studies have explored its role as a privileged structure for designing novel enzyme inhibitors and receptor modulators, leveraging its unique physicochemical properties and binding capabilities.

A 2023 study published in the Journal of Medicinal Chemistry demonstrated the compound's utility as a precursor for developing potent kinase inhibitors. Researchers modified the ethyl ester moiety at position 4 while preserving the quinoline core, creating derivatives with improved selectivity against specific cancer targets. The study reported IC50 values in the nanomolar range for several synthesized compounds against EGFR and VEGFR2 kinases, highlighting the structural advantages of the 10447-29-7 scaffold.

In antimicrobial applications, a 2024 research paper in Bioorganic Chemistry revealed that Ethyl quinoline-4-carboxylate derivatives exhibited remarkable activity against drug-resistant bacterial strains. The team developed a series of hybrid molecules by conjugating the quinoline core with known pharmacophores, achieving broad-spectrum activity with MIC values as low as 0.5 μg/mL against MRSA. Molecular docking studies suggested that these compounds interfere with bacterial DNA gyrase and topoisomerase IV, providing a dual mechanism of action.

The compound's pharmacokinetic properties have also been investigated in recent preclinical studies. A 2023 publication in European Journal of Pharmaceutical Sciences reported improved metabolic stability and oral bioavailability of several 10447-29-7 derivatives compared to earlier quinoline-based drugs. Structural modifications at the 2- and 3-positions of the quinoline ring, while maintaining the ethyl carboxylate group, resulted in compounds with favorable ADME profiles and reduced cytochrome P450 inhibition.

Emerging research has explored the application of Ethyl quinoline-4-carboxylate in targeted drug delivery systems. A 2024 study in ACS Nano described the development of quinoline-functionalized nanoparticles for tumor-specific accumulation. The 10447-29-7 derivative served as both a targeting moiety and a fluorescent probe, enabling simultaneous drug delivery and imaging capabilities. This bifunctional approach demonstrated enhanced therapeutic efficacy in mouse xenograft models of breast cancer.

Ongoing clinical trials (as of Q2 2024) are evaluating several Ethyl quinoline-4-carboxylate derivatives for various indications, including non-small cell lung cancer and complicated urinary tract infections. Preliminary results suggest acceptable safety profiles and promising efficacy signals, particularly for the oncology applications. The compound's structural flexibility continues to inspire novel drug design strategies across multiple therapeutic areas.

Future research directions include exploring the compound's potential in neurodegenerative diseases and as a building block for PROTAC molecules. The unique electronic properties of the quinoline system, combined with the modifiable ester functionality, position 10447-29-7 as a valuable scaffold for next-generation therapeutics. Continued structure-activity relationship studies are expected to yield compounds with enhanced potency and selectivity across various biological targets.

• 50614-84-1(Ethyl indole-4-carboxylate)
• 82408-84-2(9H-Carbazole-4-carboxylic acid, ethyl ester)
• 5132-81-0(Methyl 9-Acridinecarboxylate)
• 71711-47-2( )
• 21233-61-4(Methyl quinoline-4-carboxylate (~90%))
• 73987-38-9(Ethyl quinoline-6-carboxylate)
• 104294-00-0(Ethyl quinoline-7-carboxylate)
• 98421-25-1(ethyl quinoline-5-carboxylate)
• 82967-39-3(5-Quinolinecarboxylic acid, 8-methyl-, ethyl ester)
• 16675-62-0(Methyl quinoline-5-carboxylate)